fluorouracil has been researched along with Erythema in 65 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Erythema: Redness of the skin produced by congestion of the capillaries. This condition may result from a variety of disease processes.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hand-foot syndrome is a localized cutaneous side effect associated with the administration of several chemotherapeutic agents, including the oralfluoropyrimidine capecitabine (Xeloda)." | 8.82 | Coming to grips with hand-foot syndrome. Insights from clinical trials evaluating capecitabine. ( Blum, J; Scheithauer, W, 2004) |
| "Capecitabine is active against anthracycline- and taxane-pretreated metastatic breast cancer." | 8.82 | Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M. D. Anderson Cancer Center and a review of capecitabine toxicity in the literature. ( Gauthier, AM; Hennessy, BT; Hortobagyi, G; Michaud, LB; Valero, V, 2005) |
| "Hand-and-foot syndrome (HFS) is one of the well-known adverse events associated with capecitabine, a prodrug of 5-fluorouracil (5-FU)." | 8.82 | Serious hand-and-foot syndrome in black patients treated with capecitabine: report of 3 cases and review of the literature. ( Hitti, IF; Narasimhan, P; Narasimhan, S; Rachita, M, 2004) |
| "We describe a 47-year-old man who developed a linear serpentine erythematous eruption, overlying the superficial veins on both arms, after treatment with intravenous 5-fluorouracil." | 8.80 | Persistent supravenous erythematous eruption: a rare local complication of intravenous 5-fluorouracil therapy. ( Alomar, A; Lopez-Pousa, A; Pujol, RM; Rocamora, V; Taberner, R, 1998) |
| "Hand-foot syndrome (HFS) is one of the most relevant dose-limiting adverse effects of capecitabine, an oral prodrug of 5-fluorouracil used in the standard treatment of breast and colorectal cancer." | 7.77 | A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome. ( Alonso, MR; Benítez, J; Caronia, D; de la Torre, J; Díaz-Rubio, E; García-Sáenz, JA; González-Neira, A; Martin, M; Moreno, LT; Pita, G; Sastre, J, 2011) |
| "Although the 2009 edition of the Guidelines for Colorectal Cancer Therapy recommend capecitabine as a standard postoperative adjuvant chemotherapy for colorectal cancer therapy, a characteristic adverse event, hand-foot syndrome, develops at a high incidence, and appropriate management is necessary to continue therapy." | 7.76 | [Adverse events in patients treated with capecitabine as adjuvant chemotherapy after surgery for colorectal cancer--countermeasures against hand-foot syndrome]. ( Chiba, M; Fujimoto, H; Igawa, A; Iizawa, H; Ikeda, E; Inoue, K; Ishiyama, K; Kobayashi, Y; Matsuda, M; Mori, N; Saito, T; Sato, T; Sugawara, M; Suto, T; Suzuki, Y; Watanabe, T; Yabuki, H, 2010) |
| "It is well known that fluorouracil (FU) agents frequently induce discoid-lupus-erythematosus (DLE)-like eruptions and acral erythema in Japan." | 7.74 | Anti-SSA/Ro antibody as a risk factor for fluorouracil-induced drug eruptions showing acral erythema and discoid-lupus-erythematosus-like lesions. ( Adachi, A; Horikawa, T; Nagai, H, 2007) |
| "Clinical characteristics and risk factors of hand-foot syndrome were investigated in patients who received capecitabine-containing chemotherapy." | 7.72 | Hand-foot syndrome in patients treated with capecitabine-containing combination chemotherapy. ( Ahn, JH; Chang, HM; Cho, HK; Heo, YS; Kang, YK; Kim, SB; Kim, TW; Kim, WK; Lee, JS; Ryu, MH, 2004) |
| "The limiting toxicity of low dose continuous infusion 5-fluorouracil (200-300 mg/m2/day) is often palmar-plantar erythrodysesthesia (PPE)." | 7.68 | Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion. ( Dahlberg, S; Fabian, CJ; Giri, S; Molina, R; Slavik, M; Stephens, R, 1990) |
| "Fluorouracil is a common cause of acral erythema and a variety of pigmentary anomalies." | 7.68 | Combination chemotherapy with 5-fluorouracil, folinic acid, and alpha-interferon producing histologic features of graft-versus-host disease. ( Beard, JS; Skelton, HG; Smith, KJ, 1993) |
| "A case of palmar-plantar erythrodysesthesia syndrome (PPES) observed during a 120-h infusion of 5-fluorouracil (5-FU) is presented." | 7.67 | Palmar-plantar erythrodysesthesia syndrome associated with short-term continuous infusion (5 days) of 5-fluorouracil. ( Bellmunt, J; Hidalgo, R; Navarro, M; Solé, LA, 1988) |
| " The dosage should be reduced or therapeutic regimen changed." | 5.34 | [Unilateral acral necrosis as a minor form of hand-foot syndrome. Patient with unilateral acral necrosis secondary to capecitabine therapy for metastatic breast cancer]. ( Ockenfels, HM; Saborowski, A; Sauter, C, 2007) |
| "Palmar-plantar erythrodysesthesia (PPE) is a distinctive and relatively frequent toxic reaction related to some chemotherapeutic agents." | 5.33 | Palmar-plantar erythrodysesthesia due to docetaxel-capecitabine therapy is treated with vitamin E without dose reduction. ( Erkisi, M; Kara, IO; Sahin, B, 2006) |
| "Patients with histologically confirmed breast cancer or colorectal cancer receiving single agent capecitabine started at 2000 to 2500 mg/m(2) daily from day 1 to 14 every 3 weeks were randomly assigned to receive 200 mg or 400 mg daily of pyridoxine for PPE prophylaxis." | 5.14 | Randomized trial of two different doses of pyridoxine in the prevention of capecitabine-associated palmar-plantar erythrodysesthesia. ( Chalermchai, T; Sriuranpong, V; Suwanrusme, H; Tantiphlachiva, K; Voravud, N, 2010) |
| "It is timely to compare the efficacy and tolerability of 2 actinic keratosis (AK) therapies--5% 5-fluorouracil (5-FU) cream and imiquimod cream." | 5.12 | Comparison of 5% 5-fluorouracil cream and 5% imiquimod cream in the management of actinic keratoses on the face and scalp. ( Tanghetti, E; Werschler, P, 2007) |
| "A phase II trial was initiated to analyze the activity of continuously administered pioglitazone and rofecoxib combined with low-dose chemotherapy (capecitabine or temozolomide) in patients with high-grade gliomas (glioblastoma or anaplastic glioma)." | 5.12 | Low-dose chemotherapy in combination with COX-2 inhibitors and PPAR-gamma agonists in recurrent high-grade gliomas - a phase II study. ( Baumgart, U; Bogdahn, U; Hau, P; Hirschmann, B; Kunz-Schughart, L; Muhleisen, H; Reichle, A; Ruemmele, P; Steinbrecher, A; Weimann, E, 2007) |
| "Hand-and-foot syndrome (HFS) is one of the well-known adverse events associated with capecitabine, a prodrug of 5-fluorouracil (5-FU)." | 4.82 | Serious hand-and-foot syndrome in black patients treated with capecitabine: report of 3 cases and review of the literature. ( Hitti, IF; Narasimhan, P; Narasimhan, S; Rachita, M, 2004) |
| "Capecitabine is active against anthracycline- and taxane-pretreated metastatic breast cancer." | 4.82 | Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M. D. Anderson Cancer Center and a review of capecitabine toxicity in the literature. ( Gauthier, AM; Hennessy, BT; Hortobagyi, G; Michaud, LB; Valero, V, 2005) |
| "Hand-foot syndrome is a localized cutaneous side effect associated with the administration of several chemotherapeutic agents, including the oralfluoropyrimidine capecitabine (Xeloda)." | 4.82 | Coming to grips with hand-foot syndrome. Insights from clinical trials evaluating capecitabine. ( Blum, J; Scheithauer, W, 2004) |
| "We describe a 47-year-old man who developed a linear serpentine erythematous eruption, overlying the superficial veins on both arms, after treatment with intravenous 5-fluorouracil." | 4.80 | Persistent supravenous erythematous eruption: a rare local complication of intravenous 5-fluorouracil therapy. ( Alomar, A; Lopez-Pousa, A; Pujol, RM; Rocamora, V; Taberner, R, 1998) |
| "We present a case of a 53-year-old female patient who was treated with 5-Fluorouracil (5-FU) after postsurgical contracture." | 4.02 | Contracture Treatment With 5-FU. ( Borrelli, M; Desales, A; Raskin, J; Talei, B, 2021) |
| "Hand-foot syndrome (HFS) is one of the most relevant dose-limiting adverse effects of capecitabine, an oral prodrug of 5-fluorouracil used in the standard treatment of breast and colorectal cancer." | 3.77 | A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome. ( Alonso, MR; Benítez, J; Caronia, D; de la Torre, J; Díaz-Rubio, E; García-Sáenz, JA; González-Neira, A; Martin, M; Moreno, LT; Pita, G; Sastre, J, 2011) |
| "Hand-foot syndrome (HFS), the most common toxicity of capecitabine, is characterized by tingling, numbness, pain, erythema, dryness, rash, swelling, increased pigmentation, and/or pruritus of the palmar and/or plantar surfaces of the hands and/or feet." | 3.76 | Unilateral hand-foot syndrome: an extraordinary side effect of capecitabine. ( Abali, H; Disel, U; Gürkut, O; Kaleağasi, H; Mertsoylu, H; Ozyilkan, O; Saif, MW, 2010) |
| "Although the 2009 edition of the Guidelines for Colorectal Cancer Therapy recommend capecitabine as a standard postoperative adjuvant chemotherapy for colorectal cancer therapy, a characteristic adverse event, hand-foot syndrome, develops at a high incidence, and appropriate management is necessary to continue therapy." | 3.76 | [Adverse events in patients treated with capecitabine as adjuvant chemotherapy after surgery for colorectal cancer--countermeasures against hand-foot syndrome]. ( Chiba, M; Fujimoto, H; Igawa, A; Iizawa, H; Ikeda, E; Inoue, K; Ishiyama, K; Kobayashi, Y; Matsuda, M; Mori, N; Saito, T; Sato, T; Sugawara, M; Suto, T; Suzuki, Y; Watanabe, T; Yabuki, H, 2010) |
| "It is well known that fluorouracil (FU) agents frequently induce discoid-lupus-erythematosus (DLE)-like eruptions and acral erythema in Japan." | 3.74 | Anti-SSA/Ro antibody as a risk factor for fluorouracil-induced drug eruptions showing acral erythema and discoid-lupus-erythematosus-like lesions. ( Adachi, A; Horikawa, T; Nagai, H, 2007) |
| "Capecitabine is an orally active fluoropyrimidine that has been approved for first-line treatment of metastatic colorectal cancer when fluoropyrimidines alone are indicated." | 3.74 | Palmar-plantar erythrodysesthesia associated with scrotal and penile involvement with capecitabine. ( DeSimone, P; Sapp, CM, 2007) |
| "Capecitabine is an antineoplastic agent that is currently the only effective treatment for patients with advanced or metastatic breast cancer in whom anthracycline or taxoid treatment has failed." | 3.72 | Onycholysis with the appearance of a "sunset" secondary to capecitabine. ( Maino, KL; Norwood, C; Stashower, ME, 2003) |
| "Clinical characteristics and risk factors of hand-foot syndrome were investigated in patients who received capecitabine-containing chemotherapy." | 3.72 | Hand-foot syndrome in patients treated with capecitabine-containing combination chemotherapy. ( Ahn, JH; Chang, HM; Cho, HK; Heo, YS; Kang, YK; Kim, SB; Kim, TW; Kim, WK; Lee, JS; Ryu, MH, 2004) |
| "Palmar-Plantar erythrodyasesthesia syndrome has been reported as a temporary complication of 5-fluorouracil therapy consisting of a debilitating erythema and tenderness of the skin of hands and feet." | 3.69 | Long-term sequelae of Palmar-Plantar erythrodysaesthesia syndrome secondary to 5-fluorouracil therapy. ( Banfield, GK; Crate, ID; Griffiths, CL, 1995) |
| "Fluorouracil is a common cause of acral erythema and a variety of pigmentary anomalies." | 3.68 | Combination chemotherapy with 5-fluorouracil, folinic acid, and alpha-interferon producing histologic features of graft-versus-host disease. ( Beard, JS; Skelton, HG; Smith, KJ, 1993) |
| "The limiting toxicity of low dose continuous infusion 5-fluorouracil (200-300 mg/m2/day) is often palmar-plantar erythrodysesthesia (PPE)." | 3.68 | Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion. ( Dahlberg, S; Fabian, CJ; Giri, S; Molina, R; Slavik, M; Stephens, R, 1990) |
| "One day after sunbathing, a breast cancer patient received intravenous methotrexate, cyclophosphamide and 5-fluorouracil and had a recall of her UV erythema over the following week." | 3.67 | Recall of UVB-induced erythema in breast cancer patient receiving multiple drug chemotherapy. ( Andersen, KE; Lindskov, R, 1984) |
| "A case of palmar-plantar erythrodysesthesia syndrome (PPES) observed during a 120-h infusion of 5-fluorouracil (5-FU) is presented." | 3.67 | Palmar-plantar erythrodysesthesia syndrome associated with short-term continuous infusion (5 days) of 5-fluorouracil. ( Bellmunt, J; Hidalgo, R; Navarro, M; Solé, LA, 1988) |
| "Surgical scars are best treated with a combination approach to address various features of the scar." | 2.53 | A Combination Approach to Surgical Scars. ( Cohen, JL; Eilers, RE; Ortiz, AE; Ross, EV, 2016) |
| "Palmar-plantar erythrodysesthesia (PPE) or hand-foot syndrome (HFS) is a relatively common side effect of cytotoxic chemotherapy." | 2.44 | Palmar-plantar erythrodysesthesia (PPE): a literature review with commentary on experience in a cancer centre. ( Harrold, K; How, C; Webster-Gandy, JD, 2007) |
| "Oral mucositis was induced in 60 male hamsters by 5-FU (60 mg/kg) on days 0, 5, and 10 of the study." | 1.39 | Healing acceleration in hamsters of oral mucositis induced by 5-fluorouracil with topical Calendula officinalis. ( Amanat, D; Garcia-Godoy, F; Saghiri, MA; Samani, SM; Tadbir, AA; Tamadon, A; Tanideh, N; Tavakoli, P, 2013) |
| " The dosage should be reduced or therapeutic regimen changed." | 1.34 | [Unilateral acral necrosis as a minor form of hand-foot syndrome. Patient with unilateral acral necrosis secondary to capecitabine therapy for metastatic breast cancer]. ( Ockenfels, HM; Saborowski, A; Sauter, C, 2007) |
| "Palmar-plantar erythrodysesthesia (PPE) is a distinctive and relatively frequent toxic reaction related to some chemotherapeutic agents." | 1.33 | Palmar-plantar erythrodysesthesia due to docetaxel-capecitabine therapy is treated with vitamin E without dose reduction. ( Erkisi, M; Kara, IO; Sahin, B, 2006) |
| "Oral mucositis is a frequent side-effect of cancer therapy." | 1.33 | Effects of the tumour necrosis factor-alpha inhibitors pentoxifylline and thalidomide in short-term experimental oral mucositis in hamsters. ( Augusto, RF; Brito, GA; Cunha, FQ; Falcão, BA; Leitão, BT; Lima, V; Rebouças, CG; Ribeiro, RA; Souza, ML, 2005) |
| "5-Fluorouracil (5-FU) is an antimetabolite frequently used in the treatment of cancer." | 1.29 | Dermatological toxicity from chemotherapy containing 5-fluorouracil. ( Campanella, GA; Carrieri, G; Colucci, G; Leo, S; Tatulli, C; Taveri, R, 1994) |
| "Ten patients completed a weekly pulse dosing regimen for topical 5-fluorouracil therapy for multiple facial actinic keratoses." | 1.28 | Weekly pulse dosing: effective and comfortable topical 5-fluorouracil treatment of multiple facial actinic keratoses. ( Pearlman, DL, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 19 (29.23) | 18.7374 |
| 1990's | 13 (20.00) | 18.2507 |
| 2000's | 20 (30.77) | 29.6817 |
| 2010's | 11 (16.92) | 24.3611 |
| 2020's | 2 (3.08) | 2.80 |
| Authors | Studies |
|---|---|
| Talei, B | 1 |
| Raskin, J | 1 |
| Borrelli, M | 1 |
| Desales, A | 1 |
| Maarouf, M | 2 |
| Kromenacker, BW | 2 |
| Brucks, ES | 2 |
| Hendricks, A | 1 |
| Shi, VY | 2 |
| Hendricks, AJ | 1 |
| Eilers, RE | 1 |
| Ross, EV | 1 |
| Cohen, JL | 1 |
| Ortiz, AE | 1 |
| Lee, YJ | 1 |
| Lee, HJ | 1 |
| Jeong, KC | 1 |
| Kang, JG | 1 |
| Lee, SH | 1 |
| Kim, YT | 1 |
| López, V | 1 |
| Martín, JM | 1 |
| Jordá, E | 1 |
| Disel, U | 1 |
| Gürkut, O | 1 |
| Abali, H | 1 |
| Kaleağasi, H | 1 |
| Mertsoylu, H | 1 |
| Ozyilkan, O | 1 |
| Saif, MW | 1 |
| Suto, T | 1 |
| Ishiyama, K | 1 |
| Yabuki, H | 1 |
| Mori, N | 1 |
| Inoue, K | 1 |
| Chiba, M | 1 |
| Igawa, A | 1 |
| Watanabe, T | 1 |
| Fujimoto, H | 1 |
| Suzuki, Y | 1 |
| Sugawara, M | 1 |
| Saito, T | 1 |
| Kobayashi, Y | 1 |
| Matsuda, M | 1 |
| Ikeda, E | 1 |
| Sato, T | 1 |
| Iizawa, H | 1 |
| Jeung, HC | 1 |
| Chung, HC | 1 |
| Chalermchai, T | 1 |
| Tantiphlachiva, K | 1 |
| Suwanrusme, H | 1 |
| Voravud, N | 1 |
| Sriuranpong, V | 1 |
| Caronia, D | 1 |
| Martin, M | 1 |
| Sastre, J | 1 |
| de la Torre, J | 1 |
| García-Sáenz, JA | 1 |
| Alonso, MR | 1 |
| Moreno, LT | 1 |
| Pita, G | 1 |
| Díaz-Rubio, E | 1 |
| Benítez, J | 1 |
| González-Neira, A | 1 |
| Fleta-Asín, B | 1 |
| Alcántara-González, J | 1 |
| Alonso-Castro, L | 1 |
| Truchuelo-Díez, M | 1 |
| Jaén-Olasolo, P | 1 |
| Ciccolini, J | 1 |
| Evrard, A | 1 |
| Lacarelle, B | 1 |
| Tanideh, N | 1 |
| Tavakoli, P | 1 |
| Saghiri, MA | 1 |
| Garcia-Godoy, F | 1 |
| Amanat, D | 1 |
| Tadbir, AA | 1 |
| Samani, SM | 1 |
| Tamadon, A | 1 |
| Emens, LA | 1 |
| Kennedy, MJ | 1 |
| Fetting, JH | 1 |
| Davidson, NE | 1 |
| Garrett, E | 1 |
| Armstrong, DK | 1 |
| SCHELL, HW | 1 |
| FALKSON, G | 1 |
| SCHULZ, EJ | 1 |
| Childress, J | 1 |
| Lokich, J | 1 |
| Maino, KL | 1 |
| Norwood, C | 1 |
| Stashower, ME | 1 |
| Narasimhan, P | 1 |
| Narasimhan, S | 1 |
| Hitti, IF | 1 |
| Rachita, M | 1 |
| Heo, YS | 1 |
| Chang, HM | 1 |
| Kim, TW | 1 |
| Ryu, MH | 1 |
| Ahn, JH | 1 |
| Kim, SB | 1 |
| Lee, JS | 1 |
| Kim, WK | 1 |
| Cho, HK | 1 |
| Kang, YK | 1 |
| Scheithauer, W | 1 |
| Blum, J | 1 |
| Wilkes, GM | 1 |
| Doyle, D | 1 |
| Hennessy, BT | 1 |
| Gauthier, AM | 1 |
| Michaud, LB | 1 |
| Hortobagyi, G | 1 |
| Valero, V | 1 |
| Lima, V | 1 |
| Brito, GA | 1 |
| Cunha, FQ | 1 |
| Rebouças, CG | 1 |
| Falcão, BA | 1 |
| Augusto, RF | 1 |
| Souza, ML | 1 |
| Leitão, BT | 1 |
| Ribeiro, RA | 1 |
| Kara, IO | 1 |
| Sahin, B | 1 |
| Erkisi, M | 1 |
| Lemperle, G | 1 |
| Rullan, PP | 1 |
| Gauthier-Hazan, N | 1 |
| Peramiquel, L | 1 |
| Dalmau, J | 1 |
| Puig, L | 1 |
| Roé, E | 1 |
| Fernández-Figueras, MT | 1 |
| Alomar, A | 2 |
| Sauter, C | 1 |
| Saborowski, A | 1 |
| Ockenfels, HM | 1 |
| Adachi, A | 1 |
| Nagai, H | 1 |
| Horikawa, T | 1 |
| Sapp, CM | 1 |
| DeSimone, P | 1 |
| Webster-Gandy, JD | 1 |
| How, C | 1 |
| Harrold, K | 1 |
| Tanghetti, E | 1 |
| Werschler, P | 1 |
| Hau, P | 1 |
| Kunz-Schughart, L | 1 |
| Bogdahn, U | 1 |
| Baumgart, U | 1 |
| Hirschmann, B | 1 |
| Weimann, E | 1 |
| Muhleisen, H | 1 |
| Ruemmele, P | 1 |
| Steinbrecher, A | 1 |
| Reichle, A | 1 |
| Lokich, JJ | 1 |
| Moore, C | 1 |
| Andersen, KE | 1 |
| Lindskov, R | 1 |
| Allen, BJ | 1 |
| Parker, D | 1 |
| Wright, AL | 1 |
| Banfield, GK | 1 |
| Crate, ID | 1 |
| Griffiths, CL | 1 |
| Estève, E | 1 |
| Schillio, Y | 1 |
| Vaillant, L | 1 |
| Bensaid, P | 1 |
| Missonnier, F | 1 |
| Metman, EH | 1 |
| Lorette, G | 1 |
| Leo, S | 1 |
| Tatulli, C | 1 |
| Taveri, R | 1 |
| Campanella, GA | 1 |
| Carrieri, G | 1 |
| Colucci, G | 1 |
| Sollitto, RB | 1 |
| Frank, W | 1 |
| Palko, MJ | 1 |
| Rogers, GS | 1 |
| Beard, JS | 1 |
| Smith, KJ | 1 |
| Skelton, HG | 1 |
| Bataille, V | 1 |
| Cunningham, D | 1 |
| Mansi, J | 1 |
| Mortimer, P | 1 |
| Iurlo, A | 1 |
| Fornier, M | 1 |
| Caldiera, S | 1 |
| Bertoni, F | 1 |
| Foa, P | 1 |
| Pujol, RM | 1 |
| Rocamora, V | 1 |
| Lopez-Pousa, A | 1 |
| Taberner, R | 1 |
| Bos, AM | 1 |
| van der Graaf, WT | 1 |
| Willemse, PH | 1 |
| Miyamoto, K | 1 |
| Tanaka, T | 1 |
| Isawa, S | 1 |
| Yamashita, T | 1 |
| Matsuda, A | 1 |
| Sahl, WJ | 1 |
| Taira, JW | 1 |
| Pearlman, DL | 1 |
| Griffin, TD | 1 |
| Van Scott, EJ | 1 |
| Fabian, CJ | 1 |
| Molina, R | 1 |
| Slavik, M | 1 |
| Dahlberg, S | 1 |
| Giri, S | 1 |
| Stephens, R | 1 |
| Curran, CF | 1 |
| Luce, JK | 1 |
| Altimari, AF | 1 |
| Bhoopalam, N | 1 |
| O'Dorsio, T | 1 |
| Lange, CL | 1 |
| Sandberg, L | 1 |
| Prinz, RA | 1 |
| Dudley, K | 1 |
| Micetich, K | 1 |
| Massa, MC | 1 |
| Bellmunt, J | 1 |
| Navarro, M | 1 |
| Hidalgo, R | 1 |
| Solé, LA | 1 |
| Arbuck, SG | 1 |
| Douglass, HO | 1 |
| Trave, F | 1 |
| Milliron, S | 1 |
| Baroni, M | 1 |
| Nava, H | 1 |
| Emrich, LJ | 1 |
| Rustum, YM | 1 |
| Levantine, A | 1 |
| Almeyda, J | 1 |
| Weinstein, GD | 1 |
| Peck, GL | 1 |
| Cherrick, HM | 1 |
| Weissman, D | 1 |
| Kagan, AR | 1 |
| Belisario, JC | 1 |
| Thivolet, J | 1 |
| Chabanon, M | 1 |
| Perrot, H | 1 |
| Ippen, H | 2 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Use of Cryotherapy to Prevent Paclitaxel-induced Peripheral Neuropathy and Nail Changes in Women With Breast Cancer[NCT04558034] | 14 participants (Actual) | Interventional | 2020-08-04 | Terminated (stopped due to Principal Investigator retired before study completed.) | |||
| A Phase II, Randomised Controlled Trial to Evaluate the Efficacy and Safety of Moisturising Creams With or Without Palm-oil-derived Vitamin E Concentrate in Addition to Urea-based Cream or Urea-based Cream Alone in Capecitabine-associated Palmar-Plantar E[NCT05939726] | 90 participants (Anticipated) | Interventional | 2023-05-16 | Recruiting | |||
| Effect of Topical Diclofenac on Clinical Outcome in Breast Cancer Patients Treated With Capecitabine: A Randomized Controlled Trial.[NCT05641246] | Phase 2 | 66 participants (Anticipated) | Interventional | 2022-12-08 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
9 reviews available for fluorouracil and Erythema
| Article | Year |
|---|---|
A Combination Approach to Surgical Scars.
Topics: Adrenal Cortex Hormones; Antimetabolites, Antineoplastic; Atrophy; Cicatrix; Combined Modality Thera | 2016 |
Serious hand-and-foot syndrome in black patients treated with capecitabine: report of 3 cases and review of the literature.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Black People; Capecitabine; Deoxycytidine; Erythema; F | 2004 |
Coming to grips with hand-foot syndrome. Insights from clinical trials evaluating capecitabine.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine | 2004 |
Palmar-plantar erythrodysesthesia.
Topics: Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Doxorubicin; Drug Eruptions; Erythema; Fem | 2005 |
Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M. D. Anderson Cancer Center and a review of capecitabine toxicity in the literature.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Clinical Trials, Phase | 2005 |
Avoiding and treating dermal filler complications.
Topics: Adipose Tissue; Adrenal Cortex Hormones; Animals; Autoimmune Diseases; Biocompatible Materials; Catt | 2006 |
Palmar-plantar erythrodysesthesia (PPE): a literature review with commentary on experience in a cancer centre.
Topics: Activities of Daily Living; Antineoplastic Agents; Cancer Care Facilities; Cryotherapy; Cytarabine; | 2007 |
Persistent supravenous erythematous eruption: a rare local complication of intravenous 5-fluorouracil therapy.
Topics: Antimetabolites, Antineoplastic; Dermis; Drug Eruptions; Erythema; Fluorouracil; Follow-Up Studies; | 1998 |
Drug reactions. XXIV. Cutaneous reactions to cytostatic agents.
Topics: Alopecia; Aminopterin; Antineoplastic Agents; Asparaginase; Azathioprine; Bleomycin; Busulfan; Chlor | 1974 |
6 trials available for fluorouracil and Erythema
| Article | Year |
|---|---|
Reducing unpleasant side effects of topical 5-Fluorouracil treatment for actinic keratosis: a randomized controlled trial.
Topics: Administration, Topical; Adolescent; Adult; Aged; Aged, 80 and over; Clobetasol; Double-Blind Method | 2020 |
Randomized trial of two different doses of pyridoxine in the prevention of capecitabine-associated palmar-plantar erythrodysesthesia.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Col | 2010 |
A phase I toxicity and feasibility trial of sequential dose-dense induction chemotherapy with doxorubicin, paclitaxel, and 5-fluorouracil followed by high dose consolidation for high-risk primary breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Breast Neoplasms; Diarrhea; | 2002 |
Comparison of 5% 5-fluorouracil cream and 5% imiquimod cream in the management of actinic keratoses on the face and scalp.
Topics: Administration, Topical; Adult; Aminoquinolines; Disease Management; Erythema; Facial Dermatoses; Fl | 2007 |
Low-dose chemotherapy in combination with COX-2 inhibitors and PPAR-gamma agonists in recurrent high-grade gliomas - a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Capecitabin | 2007 |
Use of pyruvic acid in the treatment of actinic keratoses: a clinical and histopathologic study.
Topics: Administration, Cutaneous; Drug Therapy, Combination; Erythema; Fluorouracil; Humans; Keratosis; Pyr | 1991 |
50 other studies available for fluorouracil and Erythema
| Article | Year |
|---|---|
Contracture Treatment With 5-FU.
Topics: Abscess; Anti-Bacterial Agents; Contracture; Dermatologic Agents; Drainage; Erythema; Face; Female; | 2021 |
5-fluorouracil-induced erythema and transepidermal water loss associated with complete actinic keratosis resolution.
Topics: Aged; Aged, 80 and over; Body Water; Epidermis; Erythema; Female; Fluorouracil; Humans; Keratosis, A | 2019 |
An unusual presentation of hand-foot syndrome at the hidden area: the scrotum and penis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Administration Schedul | 2009 |
Severe palmar-plantar erytrodysesthesia after treatment with capecitabine.
Topics: Antineoplastic Agents; Blister; Breast Neoplasms; Capecitabine; Deoxycytidine; Erythema; Female; Flu | 2010 |
Unilateral hand-foot syndrome: an extraordinary side effect of capecitabine.
Topics: Aged; Antimetabolites, Antineoplastic; Atrophy; Capecitabine; Deoxycytidine; Dihydropyrimidine Dehyd | 2010 |
[Adverse events in patients treated with capecitabine as adjuvant chemotherapy after surgery for colorectal cancer--countermeasures against hand-foot syndrome].
Topics: Adult; Aged; Aged, 80 and over; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycyt | 2010 |
Is pyridoxine helpful in preventing palmar-plantar erythrodysesthesia associated with capecitabine?
Topics: Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Erythema; Fl | 2010 |
A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Base Sequence; Binding Sites; Breas | 2011 |
Genital erythrodysesthesia as a severe manifestation of capecitabine therapy: a report of 3 cases.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Erythema; Flu | 2011 |
A CDD polymorphism as predictor of capecitabine-induced hand-foot syndrome--letter.
Topics: Antimetabolites, Antineoplastic; Cytidine Deaminase; Deoxycytidine; Erythema; Female; Fluorouracil; | 2012 |
Healing acceleration in hamsters of oral mucositis induced by 5-fluorouracil with topical Calendula officinalis.
Topics: Abscess; Animals; Antimetabolites, Antineoplastic; Calendula; Carboxymethylcellulose Sodium; Criceti | 2013 |
CURRENT STATUS OF 5-FLUOROURACIL THERAPY IN FAR-ADVANCED NEOPLASTIC DISEASE.
Topics: Alopecia; Chlorpromazine; Diarrhea; Erythema; Fluorouracil; Leukopenia; Nausea; Neoplasms; Thrombocy | 1964 |
SKIN CHANGES CAUSED BY CANCER CHEMOTHERAPY.
Topics: Alopecia; Anti-Bacterial Agents; Antibiotics, Antitubercular; Antineoplastic Agents; Cyclophosphamid | 1964 |
Cutaneous hand and foot toxicity associated with cancer chemotherapy.
Topics: Antineoplastic Agents; Docetaxel; Doxorubicin; Drug Eruptions; Erythema; Fluorouracil; Foot; Hand; H | 2003 |
Onycholysis with the appearance of a "sunset" secondary to capecitabine.
Topics: Adult; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Erythema; Fem | 2003 |
Hand-foot syndrome in patients treated with capecitabine-containing combination chemotherapy.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cli | 2004 |
Effects of the tumour necrosis factor-alpha inhibitors pentoxifylline and thalidomide in short-term experimental oral mucositis in hamsters.
Topics: Abscess; Animals; Antimetabolites, Antineoplastic; Cricetinae; Disease Models, Animal; Edema; Erythe | 2005 |
Palmar-plantar erythrodysesthesia due to docetaxel-capecitabine therapy is treated with vitamin E without dose reduction.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capecita | 2006 |
Palmar-plantar erythrodysesthesia due to docetaxel-capecitabine therapy is treated with vitamin E without dose reduction.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capecita | 2006 |
Palmar-plantar erythrodysesthesia due to docetaxel-capecitabine therapy is treated with vitamin E without dose reduction.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capecita | 2006 |
Palmar-plantar erythrodysesthesia due to docetaxel-capecitabine therapy is treated with vitamin E without dose reduction.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capecita | 2006 |
Inflammation of actinic keratoses and acral erythrodysesthesia during capecitabine treatment.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Capecitabine; Colonic Neoplasms; Deoxycytidin | 2006 |
[Unilateral acral necrosis as a minor form of hand-foot syndrome. Patient with unilateral acral necrosis secondary to capecitabine therapy for metastatic breast cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Erythema; Fema | 2007 |
Anti-SSA/Ro antibody as a risk factor for fluorouracil-induced drug eruptions showing acral erythema and discoid-lupus-erythematosus-like lesions.
Topics: Aged; Antimetabolites, Antineoplastic; Autoantibodies; Biopsy; Diagnosis, Differential; Drug Eruptio | 2007 |
Palmar-plantar erythrodysesthesia associated with scrotal and penile involvement with capecitabine.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Erythema; | 2007 |
Chemotherapy-associated palmar-plantar erythrodysesthesia syndrome.
Topics: Antineoplastic Agents; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; | 1984 |
Recall of UVB-induced erythema in breast cancer patient receiving multiple drug chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Erythema; Female | 1984 |
Reticulate pigmentation due to 5-fluorouracil.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Erythema; Fluorouracil; Humans | 1995 |
Long-term sequelae of Palmar-Plantar erythrodysaesthesia syndrome secondary to 5-fluorouracil therapy.
Topics: Erythema; Fluorouracil; Humans; Male; Middle Aged; Paresthesia | 1995 |
[Efficacy of sequential corticotherapy in a case of painful acral erythema caused by high-dose 5-fluorouracil].
Topics: Aged; Dose-Response Relationship, Drug; Erythema; Female; Fluorouracil; Humans; Pain Management; Pre | 1995 |
Dermatological toxicity from chemotherapy containing 5-fluorouracil.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Rel | 1994 |
An oncology patient with an erythematous papulosquamous eruption in sun-exposed areas. Inflamed actinic keratoses due to systemic chemotherapy (fluorouracil and, possibly, interferon alfa).
Topics: Colonic Neoplasms; Erythema; Fluorouracil; Humans; Interferon-alpha; Keratosis; Male; Middle Aged; S | 1994 |
Combination chemotherapy with 5-fluorouracil, folinic acid, and alpha-interferon producing histologic features of graft-versus-host disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Eruptions; Erythema; Female; Fluorouracil; Graf | 1993 |
Inflammation of solar keratoses following systemic 5-fluorouracil.
Topics: Aged; Antimetabolites, Antineoplastic; Erythema; Female; Fluorouracil; Humans; Keratosis; Male | 1996 |
Palmar-plantar erythrodysaesthesia syndrome due to 5-fluorouracil therapy--an underestimated toxic event?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Erythema; Female; F | 1997 |
A new conservative approach to extravasation of anthracyclines with dimethylsulfoxide and dexrazoxane.
Topics: Adult; Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; C | 2001 |
[Toxicological studies of bleomycin ointment. Irritative effect of bleomycin ointment on eye mucous membrane and skin (author's transl)].
Topics: Administration, Topical; Animals; Bleomycin; Conjunctiva; Conjunctivitis; Cornea; Erythema; Eye; Eye | 1975 |
Erythema ab igne: treatment with 5-fluorouracil cream.
Topics: Administration, Topical; Aged; Erythema; Female; Fluorouracil; Humans; Infrared Rays; Pigmentation D | 1992 |
Weekly pulse dosing: effective and comfortable topical 5-fluorouracil treatment of multiple facial actinic keratoses.
Topics: Administration, Cutaneous; Drug Administration Schedule; Erythema; Facial Dermatoses; Fluorouracil; | 1991 |
Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion.
Topics: Colonic Neoplasms; Edema; Erythema; Fluorouracil; Follow-Up Studies; Foot Dermatoses; Hand Dermatose | 1990 |
Fluorouracil and palmar-plantar erythrodysesthesia.
Topics: Erythema; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Pain | 1989 |
Use of a somatostatin analog (SMS 201-995) in the glucagonoma syndrome.
Topics: Adenoma, Islet Cell; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dacarbaz | 1986 |
Erythema with features of seborrheic dermatitis and lupus erythematosus associated with systemic 5-fluorouracil.
Topics: Aged; Dermatitis, Seborrheic; Erythema; Fluorouracil; Humans; Lupus Erythematosus, Cutaneous; Male; | 1987 |
Palmar-plantar erythrodysesthesia syndrome associated with short-term continuous infusion (5 days) of 5-fluorouracil.
Topics: Carcinoma, Squamous Cell; Erythema; Fluorouracil; Foot; Hand; Humans; Male; Middle Aged; Paresthesia | 1988 |
A phase II trial of 5-fluorouracil and high-dose intravenous leucovorin in gastric carcinoma.
Topics: Adenocarcinoma; Bone Marrow Diseases; Diarrhea; Drug Evaluation; Erythema; Fluorouracil; Humans; Inj | 1987 |
Epithelial neoplasms.
Topics: Administration, Topical; Antineoplastic Agents; Erythema; Fluorouracil; Humans; Keratosis; Prostagla | 1974 |
Hypertrophic scar after cryotherapy and topical tretinoin.
Topics: Administration, Topical; Carcinoma, Basal Cell; Carmustine; Cicatrix; Connective Tissue; Cryosurgery | 1973 |
Effects of topically applied 5-fluorouracil in the Syrian hamster.
Topics: Administration, Topical; Animals; Cheek; Cricetinae; Erythema; Fluorouracil; Mouth Mucosa; Necrosis; | 1974 |
Comments on morbidity in present-day radiotherapy.
Topics: Breast Neoplasms; Buttocks; Carcinoma, Squamous Cell; Dactinomycin; Erythema; Female; Fluorouracil; | 1971 |
Topical cytotoxic therapy of solar keratoses with 5-fluorouracil.
Topics: Antineoplastic Agents; Dermatologic Agents; Erythema; Fluorouracil; Humans; Keratosis; Male; Ointmen | 1969 |
[Use of 5-fluorouracil ointment. Indications and limitations].
Topics: Carcinoma, Squamous Cell; Erythema; Fluorouracil; Humans; Keratosis; Ointments; Photosensitivity Dis | 1970 |
The photoprotective effect and pharmaceutical properties of 5-fluorouracil ointment.
Topics: Chemical Phenomena; Chemistry; Erythema; Fluorouracil; Light; Ointments; Time Factors | 1970 |
[Investigations in cutaneous light physiology I. Erythema protection by external applied 5-fluorouracil].
Topics: Erythema; Fluorouracil; Humans; Photosensitivity Disorders; Skin; Skin Physiological Phenomena; Sunl | 1969 |